The pharma rep isn't disappearing. The territory is

Melonie WarfelChief Commercial Officer, SwishX·9 min read
Contents
  1. Introduction
  2. The headcount fell, then came back with a different job
  3. Access closed fastest where the new medicines are
  4. The medicines changed, and so did the conversation
  5. Two questions tell you what a field force should look like
  6. The account rep's real job is coordination
  7. Training becomes the competitive variable
  8. What I would change on Monday

Rep headcount has come back, yet access keeps shrinking and the call-volume model looks older every year. What is ending is the territory, and what replaces it makes judgment in the room, and how reps are trained for it, the real competitive variable.

Every few years someone writes the obituary of the pharmaceutical sales rep, and every few years the headcount refuses to cooperate. ZS put the US field force at about 102,000 reps at its 2005 peak and 61,900 in the second half of 2013. By 2023 it estimated that positions had rebounded to around 81,000. That is not the shape of a dying job.

What is dying is the territory: the map of zip codes, the call plan built on reach and frequency, the assumption that a rep earns their keep by the number of doors they get through in a week. That model was designed for primary-care blockbusters and for doctors who mostly said yes to a visit. Neither condition holds for most of what we launch now.

What replaces it is a smaller, more expert field force organized around accounts, whose value is concentrated in a few minutes of judgment in front of a specialist with hard questions. If that's right, the variable that separates winners over the next decade is not how many reps a company has. It is how good they are in the room, and whether anyone can tell before the meeting happens.

The headcount fell, then came back with a different job

The decline from the 2005 peak is the part of the story everyone remembers. It belonged to an era in which a handful of primary-care brands, sold to tens of thousands of general practitioners, justified very large sales forces calling on the same offices in rotation. When those brands lost exclusivity and the pipeline moved elsewhere, the reach model lost the products it was built to sell.

The rebound gets less attention, and it is more interesting. The roughly 81,000 positions ZS estimated in 2023 are not the same jobs as the 102,000 of 2005. The same reporting describes an industry that has moved deep into specialty medicines, health systems and pharmacy benefit managers consolidated enough to need key account teams, and the rise of so-called hybrid reps who work across channels.

In other words, companies did not stop paying for people in the field. They stopped paying for coverage and started paying for something else. Most organizations have not been explicit about what that something else is, which is why so many field forces still carry the territory's metrics, training and incentive plans into a job that no longer resembles it.

Access closed fastest where the new medicines are

Access to physicians has been eroding for as long as anyone has measured it. ZS's AccessMonitor found nearly 80% of US physicians accessible to reps in 2009, and by 2015 to 2017 the figure sat in the 45 to 50% range. Veeva's Pulse data, drawn from the CRM activity of more than 80% of the industry's field teams, showed the same pattern after the pandemic bounce: in 2024, 45% of US HCPs were accessible, down from 60% eighteen months earlier.

The average hides the important part. Restriction is heaviest in exactly the specialties where the pipeline is. In 2010, ZS labeled 75% of oncologists accessible. By 2015, 73% were access-restricted. Veeva's 2024 data found that half of accessible HCPs meet with three or fewer companies, and that nearly 30% of physicians in internal medicine, oncology, psychiatry and urology restrict access to just one.

Europe got there by rule rather than by drift. In the UK, the 2024 ABPI Code says a rep may call on a doctor or other prescriber no more than three times a year on average, and Veeva puts average access across the five largest European markets at 53%. When a rep may see a doctor three times a year, nobody pretends the visit is about frequency.

That is the point I would hold onto. The UK is not an outlier US teams can ignore. It is a preview of what an American oncologist's calendar already looks like.

The medicines changed, and so did the conversation

Specialty medicines made up 54% of US medicine spending in IQVIA's 2024 analysis, up from 49% in 2018. Of the 46 novel drugs FDA's drug center approved in 2025, 23 carried orphan drug designation. The center of gravity of what we launch is now a therapy for a defined population, often identified by a biomarker or a diagnosis that takes years to reach, and prescribed by a relatively small number of specialists.

That changes what a conversation with a physician is about. Part of my career was spent on pricing and revenue management, and from that side of the business it is obvious that a specialty product conversation is rarely only about efficacy. It is about which patients qualify under the label, what the prior authorization asks for, which specialty pharmacy dispenses the drug, what the hub does, how safety monitoring works, and who in the practice handles each of those steps. A rep who can only deliver the core message is not much use in that meeting, and the physician knows it within a minute.

It also puts the rep constantly at the edge of what they are allowed to say. Questions about populations outside the label, comparisons the label does not support, data from a congress poster: these come up more in specialty conversations, not less, because the physician is close to the science. The right answer is often a handoff to medical, made well and on time. The line between what a rep can say and what an MSL can say is narrower than most training admits, and in a specialist's office it gets tested every week.

Two questions tell you what a field force should look like

When I try to reason about field models, two questions do most of the work. How often can we realistically get in front of this customer? And how hard is the conversation once we are there?

Put them together and you get four situations. Where access is open and the conversation is simple, you have the old territory, and it is the situation that matters least now, because a message the doctor already understands can travel by email, a website or an inside sales team at a fraction of the cost. Where access is restricted and the conversation is simple, digital and remote channels should carry most of the load. Where access is open and the conversation is hard, as with some academic centers and engaged specialists, medical and commercial teams can afford to take their time.

The fourth situation is the one that now defines most launches: restricted access and a hard conversation. There are few meetings, each one decisive, with a specialist who has read the trial and wants to talk about the subgroup that did not fit the headline. One poor answer can cost the account for a year, and no volume of follow-up email will repair it.

In that corner, nearly every territory-era habit points the wrong way. Call frequency is close to meaningless. Reach is decided by the account, not the rep. What matters is preparation, the quality of the answer and what happens in the days after the meeting. The field force you need there is smaller, more senior, more scientifically literate and organized around accounts and the people inside them, which is roughly what the industry has been hiring toward without quite saying so.

The account rep's real job is coordination

Key account management is often described as a sales role with a bigger patch. I think that undersells it. In a consolidated health system, the account includes the prescribers, the pharmacy and therapeutics committee, the pathway owners, the specialty pharmacy and the payer mix behind them. No single person in a life sciences company can cover all of that, and no physician wants five uncoordinated visitors from the same company.

Physicians notice when we get this wrong. In a Veeva survey of 50 key opinion leaders in late 2024, more than half said they engage with a company's clinical, medical and sales teams, and 44% said they see a lack of coordination and alignment between them. In an April 2025 Veeva focus group, 71% of top-20 biopharma executives said their operating model, not compliance, is what prevents effective medical-commercial collaboration. That is a striking admission. The obstacle we usually blame is not the one leaders themselves point to.

The payoff from fixing it is measurable. Veeva's data shows that field medical engagement with key opinion leaders before launch improves treatment adoption by 50%, and in one of its case studies a rep call followed by a digital touch within ten days was 30% more likely to result in a prescription. Yet 65% of HCP engagements in its data are not synchronized. The rep's value in that system lies less in delivering a message and more in knowing what should happen next and making sure it does: the MSL visit, the approved email, the access specialist, the answer to the question they could not take in the room.

The strongest argument against my view is obesity and any category like it: very large primary-care demand of the kind that seems to call for the old reach playbook. I am less sure about that category than any other. My guess is that even there the hard conversations are about who qualifies, what a plan will cover and how to manage side effects, and those reward the same judgment. But I hold that view loosely.

Training becomes the competitive variable

If the field force is smaller and each conversation carries more weight, the gap between your best rep and your median rep matters more than your headcount. In a territory model, a weak call is diluted by the next forty. In an account model, the weak call may be the only one that quarter.

Most training and certification was built for the territory. It teaches product knowledge, tests recall and confirms that a module was completed before a launch or a label change. Those things are necessary and nowhere near sufficient. They show whether a rep knows the label, not whether they can hold the line on it while a specialist pushes on subgroup data, ask a useful question about the patient in front of them, or hand off to medical without sounding evasive. A high quiz score says little about any of that.

The companies that do well in the account model will treat readiness the way they treat supply: measured continuously, owned jointly by sales, medical and compliance, and refreshed whenever the evidence moves. A competitor readout, a label update or a new payer policy should each trigger the same question. Can our people answer this well, on label, today? Most organizations cannot tell you.

There is a budget trap here. When a field force shrinks, training is an easy line to cut, because the territory model taught us to think of reps as interchangeable capacity. The account model reverses that logic. Fewer reps means each one is a bigger bet, and the cost of under-preparing them goes up, not down.

What I would change on Monday

First, redraw deployment around accounts and conversation difficulty, not geography. Take your top accounts and ask the two questions honestly. Where the answer is restricted access and hard conversations, staff them with your most experienced people and give those people fewer accounts, not more.

Second, stop rewarding coverage in those accounts. Keep activity data for planning, but judge the account team by whether the right conversations happened, whether the follow-up arrived within days and whether medical and access were brought in when they should have been.

Third, put medical, access and sales on one account plan with shared visibility. Your own executives say the operating model is the obstacle, so fix the operating model: who owns the relationship, who is told when a physician asks something only medical can answer, and how fast that answer arrives.

Fourth, make readiness a standing measure instead of a launch event. Have reps practice the hardest questions for each account before the meetings that matter, score those answers against the label, and test again when the evidence changes. Hire for scientific curiosity and for the confidence to say that a question belongs with the medical team without losing the room.

And watch Europe while you do it. Markets where a rep gets three calls a year have lived in the restricted, hard-conversation corner for a long time, and their best field teams look a lot like what US specialty teams are becoming.

The territory measured how far a rep could drive. The account will measure how well they think.

Filed underPerspectives

Keep reading

All articles

Want to see Magic Academy with your reps?

AI HCP roleplay, objection handling and rep scoring, built on your approved label.